Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study

Phase 4

Terminated

• Conditions: Myelodysplastic Syndrome; Transfusional Iron Overload
• Interventions: Drug: Deferasirox

• Registration Number: NCT01326845
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

The objective of the study is to evaluate and compare the frequency and severity of GI adverse events in different dose administration regimens. The patient population consists of low or intermediate (int-1) risk myelodysplastic syndrome (MDS) patients with transfusional iron overload. The study patients are randomized to either a morning dose of 20 mg/kg/day deferasirox or an evening dose of the same. Patients are then followed up for 6 months for any GI events and are assessed using patient reported outcomes tools e.g. a patient diary.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-03-30
• Study First Submitted QC: 2011-03-30
• Study First Posted: 2011-03-31
• Study Start: 2011-12
• Primary Completion: 2012-09
• Study Completion: 2012-09
• Results First Submitted: 2013-09-11
• Results First Submitted QC: 2013-09-11
• Results First Posted: 2013-11-15
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-01
• Last Update Posted: 2017-03-03

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Written informed consent prior to any screening procedures
• Male or female patients ≥ 18 years of age
• Patient must weigh between 45-135 kg
• Patients with low or intermediate (int-1) risk MDS, as determined by IPSS score or RA, RARS by WHO criteria. IPSS must be confirmed by a bone marrow examination within 6 months prior to study entry and must be hematologically stable

Deferasirox naïve:

Sexually active pre-menopausal female patients must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation

Read More

Exclusion Criteria

• History or current GI disease
• Systemic diseases which could prevent study treatments
• Left ventricular ejection fraction< 50 % by echo cardiography
• Serum creatinine > 1.2 x ULN at screening
• Platelet counts < 25x 109/L except in cases where guidance is already given in the local deferasirox label
• AST or ALT > 2.5 xULN at screening

Other protocol-defined inclusion/exclusion criteria may apply

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Deferasirox am	Deferasirox	Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food
Deferasirox pm	Deferasirox	Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal

Primary Outcome Measures

Name	Time	Method
Difference in the Frequency of Overall Newly Occurring GI Adverse Events (AEs) in the Two Treatment Arms	3 months	Study was prematurely terminated and not powered for efficacy. Frequency of GI AEs during the overall study period is available in the AE tables reported in the safety section.

Secondary Outcome Measures

Name	Time	Method
the Difference Between the Time From Baseline to the First Occurrence of GI AEs Between the Two Treatment Groups	3 months, 6 months	Study was prematurely terminated and not powered for efficacy.
Difference in Frequency of Specific Commonly Reported GI AEs Between the Two Treatment Groups	months 3 and 6.	Study was prematurely terminated and not powered for efficacy.
Difference in Severity of GI Symptoms, Bowel Habits and Level of Satisfaction From the Patient's Perspective Between the Two Treatment Groups	3 months, 6 months
Difference in Reducing Serum Ferritin After Each Month of Study Drug Administration Between the Two Groups	3 months, 6 months	Study was prematurely terminated and not powered for efficacy.
Difference in Frequency of Overall Newly Occurring GI AEs Between the Two Treatment Groups at Month 6.	6 months	Study was prematurely terminated and not powered for efficacy.
Difference in Severity of Overall GI AEs Between the Two Treatment Groups	months 3 and 6.	Study was prematurely terminated and not powered for efficacy.
Difference in Severity of Specific Commonly Reported GI Symptoms Between the Two Treatment Groups	months 3 and 6	Study was prematurely terminated and not powered for efficacy.
Difference in Frequency and Severity of All Non-GI AEs Between the Two Treatment Groups	months 3 and 6	Study was prematurely terminated and not powered for efficacy.

Trial Locations

Locations (1)

Novartis Investigative Site; 🇪🇸 Madrid, Spain